More drugmakers including Gilead, Biogen, BMS to hike US prices for 50 drugs Medical Dialogues Bureau2 Jan 2020 9:18 AM GMTNew Delhi: Drugmakers including Bristol-Myers Squibb Co (BMY.N), Gilead Sciences Inc (GILD.O), and Biogen Inc (BIIB.O) hiked U.S. list prices on more...
FIRST: Mylan, Micro Labs get USFDA nod for generic version of blood thinner Eliquis Medical Dialogues Bureau24 Dec 2019 4:15 AM GMTSales of Eliquis, which Bristol-Myers co-developed with Pfizer, rose 22% to $1.93 billion and made up about 30% of the Bristol-Myers' total revenues...
Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche Medical Dialogues Bureau25 Nov 2019 3:30 AM GMTMedian overall survival for patients with unresectable hepatocellular carcinoma (HCC), or that which cannot be surgically removed, getting Tecentriq...
Bristol-Myers blockbuster Opdivo fails to meet goal of brain tumour study Medical Dialogues Bureau8 Sep 2019 3:45 AM GMTThe drug, Opdivo, when used along with the current standard of care for glioblastoma multiforme, did not prevent cancer from spreading when compared...
Bristol-Myers posts strong second quarter as Eliquis, Orencia sales propel Medical Dialogues Bureau28 July 2019 3:47 AM GMTSales of Eliquis, which Bristol-Myers shares with Pfizer Inc (PFE.N), rose 24% to $2.04 billion, while Orencia sales rose 9% to $778 million, both...
Exelixis drug improves overall survival in liver cancer patients Ruby Khatun Khatun21 Oct 2017 3:42 AM GMTExelixis Inc's drug to treat a type of liver cancer improved overall survival in patients in a late-stage study that prompted an independent expert...
Bristols drug cocktail cuts kidney cancer death risk 37 percent Ruby Khatun Khatun14 Sep 2017 3:55 AM GMTMADRID: A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients,...
After melanoma surgery, Bristols Opdivo offers new care standard Ruby Khatun Khatun12 Sep 2017 3:45 AM GMTMADRID: Bristol-Myers Squibb's immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients...
Bristol-Myers stops kidney cancer drug test after early success Ruby Khatun Khatun11 Sep 2017 5:18 AM GMTBristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end...
Bayer, Johnson and Johnson in frame for bigger anti-clotting market opportunity Ruby Khatun Khatun28 Aug 2017 7:35 AM GMTFRANKFURT: Bayer and Johnson & Johnson's blockbuster clot prevention drug Xarelto was shown to cut the risk of potentially deadly strokes and...
